drug

Nicotine Lozenges

as of 2026-07-01

Add to landscape Monitor this Compare this Ask about this

at a glance

small molecule

Pre-approval / investigational in the US

Developed by GlaxoSmithKline

2 trials in the graph

Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality

small molecule

Indications

Investigational (via trials)

Schizophrenia Tobacco Use Disorder Bipolar Disorder Mental Disorders Schizophrenia Persistent Depressive Disorder Tobacco Use Disorder Mental Illness Bipolar Disorder Psychotic Disorders Recurring Major Depressive Disorder Schizoaffective Disorder

Trials

Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings

NCT05030272—Completed

First Time in Human Study With GSK1018921

NCT00527020Phase 1Completed

KOLs & investigators

Roger Vilardaga, PhD

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

developer

GlaxoSmithKline

company

trial

Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings

trial

First Time in Human Study With GSK1018921

PHASE1

trial

indication

indication

indication

indication

indication

KOL

Roger Vilardaga, PhD

KOL score —

person